UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
BUREAU OF CONSUMER PROTECTION
WASHINGTON, D.C. 20580
DEPARTMENT OF HEALTH
AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
WASHINGTON, D.C. 20740

To: www.elixirs.com / health@elixirs.com

Katheryn Jones
Homeopathy for Health
422 North Earl Road
Moses Lake, WA 98837

From: The Food and Drug Administration and the Federal Trade Commission

Date: June 8, 2010

Subject: Urgent Message from the Food and Drug Administration and Federal Trade Commission Regarding H1N1 Flu Virus-Related Products Marketed by Your Firm

WARNING LETTER

This is to advise you that the United States Food and Drug Administration (FDA) and the United States Federal Trade Commission ("FTC") have reviewed your website at the Internet address www.elixirs.com on December 22, 2009. The FDA has determined that your website offers products for sale that are intended to diagnose, mitigate, prevent, treat (including to treat the symptoms of) or cure the H1N1 Flu Virus in people. These products have not been approved or otherwise authorized by FDA for use in the diagnosis, mitigation, prevention, treatment (including treatment of symptoms), or cure of the H1N1 Flu Virus.

These products include, but are not limited to, Micro Nutrition Plus Flu Combo 2009-10, Micro Nutrition Plus Flu Influenzinum 200C, Micro Nutrition Plus Flu Kit Economy 1 oz Thymuline and 1 oz Winter Tonic, Micro Nutrition Plus Flu Protection Kit 3 Remedies, Micro Nutrition Plus Influenzinum 30C, BHI Bronchitis, BHI Bronchitis Chewable Tablets, BHI Flu Plus with Influenzinum, NaturalCare Flu Wellness Kit Flu and Respiratory Support, Heel Gallium Heel, Standard Homeopathic Nux Vomica 30C, Hyland's Nux Vomica 30X, Standard Homeopathic Nux Vomica 200C, Boiron Oscillococcinum, Micro Nutrition Plus Pnemococcinum 200C, Micro Nutrition Plus Pneumococcinum 30C, Micro Nutrition Plus Thymuline 12C Immune Support, Micro Nutrition Plus Upper Respiratory Balance, and Micro Nutrition Plus Winter Tonic Influenzinum Blend. The marketing of these products violates the Federal Food, Drug, and Cosmetic Act (FFDC Act). 21 U.S.C. §§ 331, 352. We request that you immediately cease marketing unapproved or unauthorized products for the diagnosis, mitigation, prevention, treatment (including treatment of symptoms), or cure of the H1N1 Flu Virus.

Some examples of the claims on your website include:

Micro Nutrition Plus Flu Combo 2009-10 Seasonal Influenzinum and Thymuline

Micro Nutrition Plus Flu Influenzinum 200C

Micro Nutrition Plus Flu Kit economy 1 oz Thymuline and 1 oz Winter Tonic

Micro Nutrition Plus Flu Protection Kit 3 Remedies

Micro Nutrition Plus Influenzinum 30C

BHI Bronchitis

BHI Bronchitis Chewable Tablets

BHI Flu Plus with Influenzinum

Flu Wellness Kit Flu and Respiratory Support

Heel Gallium Heel

Standard Homeopathic Nux Vomica 30C

Hyland's Nux Vomica 30X

Standard Homeopathic Nux Vomica 200C

Boiron Oscillococcinum

Micro Nutrition Plus Pneumococcinum 200C

Micro Nutrition Plus Pneumococcinum 30C

Micro Nutrition Plus Thymuline 12C Immune Support

Micro Nutrition Plus Upper Respiratory Balance\

Micro Nutrition Plus Winter Tonic Influenzinum Blend

The Secretary of Health and Human Services, under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, has determined that a public health emergency exists nationwide involving the H1N1 Flu Virus that affects or has the significant potential to affect national security. Following this determination and in response to requests from the U.S. Centers for Disease Control and Prevention, FDA issued letters authorizing the emergency use of certain unapproved and uncleared products or unapproved or uncleared uses of approved or cleared products, provided certain criteria are met, under 21 U.S.C. § 360bbb-3. The marketing and sale of unapproved or uncleared H1N1 Flu Virusrelated products that are not authorized by and used in accordance with the conditions of an Emergency Use Authorization, is a potentially significant threat to the public health. Therefore, FDA is taking urgent measures to protect consumers from products that, without approval or authorization by FDA, claim to diagnose, mitigate, prevent, treat (including to treat the symptoms of) or cure H1N1 Flu Virus in people.

We recognize that the labeling for your product(s) listed above identifies them as homeopathic drug products with active ingredient(s) measured in homeopathic strength(s)—Micro Nutrition Plus Flu Combo 2009-10 30C, Micro Nutrition Plus Flu Influenzinum 200C, Micro Nutrition Plus Flu Kit Economy 1 oz Thymuline and 1 oz Winter Tonic 12C and 6C, Micro Nutrition Plus Flu Protection Kit 3 Remedies 12C and 6C, Micro Nutrition Plus Influenzinum 30C, BHI Bronchitis 4X, 5X, 6X, and 30X, BHI Bronchitis Chewable Tablets 4X, 5X, 6X, and 30X, BHI Flu Plus with Influenzinum 3X-200CK, NaturalCare Flu Wellness Kit Flu and Respiratory Support (Oscillococcinum 200CK), Heel Gallium Heel 2X-4X, Standard Homeopathic Nux Vomica 30C, Hyland's Nux Vomica 30X, Standard Homeopathic Nux Vomica 200C, Boiron Oscillococcinum 200CK, Micro Nutrition Plus Pnemococcinum 200C, Micro Nutrition Plus Pneumococcinum 30C, Micro Nutrition Plus Thymuline 12C Immune Support, Micro Nutrition Plus Upper Respiratory Balance 6C, and Micro Nutrition Plus Winter Tonic Influenzinum Blend 6C. Nothing in the FFDC Act or the regulations issued under it exempts homeopathic drugs, including homeopathic biological products, from the regulatory requirements of the FFDC Act or its implementing regulations. We acknowledge that many homeopathic drug products are manufactured and distributed without FDA approval or authorization under enforcement policies set out in the FDA's Compliance Policy Guide entitled, "Conditions Under Which Homeopathic Drugs May be Marketed (CPG 7132.15)." The enforcement discretion set forth in the CPG is not unlimited, however. The CPG states that it "delineates those conditions under which homeopathic drugs may ordinarily be marketed in the U.S." The qualifying word "ordinarily" indicates that the CPG specifically contemplates that there may be circumstances where a product that otherwise may meet the conditions set forth in the CPG may nevertheless be subject to enforcement action.

As stated above, the Secretary of Health and Human Services has determined that a public health emergency exists nationwide involving the H1N1 Flu Virus that affects or has the significant potential to affect national security. A homeopathic drug product, including a homeopathic biological product, marketed without approval or authorization is not subject to the enforcement discretion set forth in the CPG when there is a nationwide public health emergency involving the disease that the product is intended to be used to diagnose, mitigate, prevent, treat (including to treat the symptoms of), or cure. Under these circumstances, the enforcement discretion set forth in the CPG does not apply to an unapproved or unauthorized product, regardless of its homeopathic status.

You should take immediate action to ensure that your firm is not marketing, and does not market in the future, products intended to diagnose, mitigate, prevent, treat (including to treat the symptoms of) or cure the H1N1 Flu Virus that have not been approved, cleared, or authorized by the FDA. The above is not meant to be an all-inclusive list of violations. It is your responsibility to ensure that the products you market are in compliance with the FFDC Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that the claims you make for your products do not adulterate or misbrand the products in violation of the FFDC Act. 21 U.S.C. §§ 331, 351, or 352. Within 48 hours, please send an email to FDAFLUTASKFORCE-CDER@fda.hhs.gov describing the actions that you have taken or plan to take to address your firm's violations. If your firm fails to take corrective action immediately, FDA may take enforcement action, such as seizure or injunction for violations of the FFDC Act without further notice. Firms that fail to take corrective action may also be referred to FDA's Office of Criminal Investigations for possible criminal prosecution for violations of the FFDC Act and other federal laws.

FDA is advising consumers not to purchase or use H1N1 Flu Virus-related products offered for sale that have not been approved, cleared, or authorized by FDA. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning marketing unapproved, uncleared and unauthorized H1N1 Flu Virus-related products in violation of the FFDC Act. This list can be found at www.accessdata.fda gov/scripts/h1n1flu. Once the violative claims and/or products have been removed from your website, and these corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.

If you are not located in the United States, please note that unapproved, uncleared, or unauthorized products intended to diagnose, mitigate, prevent, treat (including to treat the symptoms of), or cure the H1N1 Flu Virus offered for importation into the United States are subject to detention and refusal of admission. We will advise the appropriate regulatory or law enforcement officials in the country from which you operate that FDA considers your product(s) listed above to be unapproved or unauthorized products that cannot be legally sold to consumers in the United States.

Please direct any inquiries concerning this letter to FDA at FDAFLUTASKFORCECDER@fda.hhs.gov or by contacting Andrea Vincent at 301-796-3751.

It is also your responsibility to ensure that the products you market are in compliance with the FTC Act. Under the FTC Act, claims that your homeopathic products prevent, treat, or cure the H1N1 Flu Virus in people must be supported by competent and reliable scientific evidence consisting of well-controlled human clinical studies. FTC staff strongly urges you to review all claims relating to the treatment, prevention, or cure of H1N1 and remove those claims not supported by competent and reliable scientific evidence. The FTC also asks that you notify it via electronic mail at flu@ftc.gov within 48 hours of the specific actions you have taken to address the agency's concerns. If you have any questions regarding compliance with the FTC Act, please contact Greg Fortsch at 202-326-3617.

Sincerely,

Deborah M. Autor, Esq Mary K. Engle
Director Associate Director
Office of Compliance Division of Advertising Practices
Center for Drug Evaluation and Research Federal Trade Commission
Food and Drug Administration

cc:

Celletech / Micro-Nutrition Plus
518 Tasman St
Madison, Wisconsin 53714
United States
customerservice@celletech.com

Heel, Inc. (BHI)
10421 Research Road SE
Albuquerque, New Mexico 87123-3423
customerservice@heelusa.com

NaturalCare, Inc.
Vintage, Building 1
North 300 West, Suite 210
Provo, Utah 84608
orders@enaturalcare.com

Hyland's Homeopathic
154 W. 131st Street
Los Angeles, California 90061
info@hylands.com

Standard Homeopathic Company
210 W. 131st Street
Los Angeles, CA 90061
epconway@hylands.ca

Boiron Borneman, Inc.
6 Campus Boulevard
Building A
Newtown Square, PA 19073
info_tech@boiron.fr

This page was posted on December 2, 2010.

Links to Recommended Companies